利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

27 条记录 (耗时 0.06 秒)

    NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION
    3.
    发明申请
    NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION 失效
    HEPATITIS C VIRUS REPLICATION的新型抑制剂

    公开(公告)号：US20080019942A1

    公开(公告)日：2008-01-24

    申请号：US11773912

    申请日：2007-07-05

    申请人： Scott Seiwert ,  Leonid Beigelman ,  Lawrence Blatt ,  Timothy Kercher ,  April Kennedy ,  Steven Andrews

    发明人： Scott Seiwert ,  Leonid Beigelman ,  Lawrence Blatt ,  Timothy Kercher ,  April Kennedy ,  Steven Andrews

    IPC分类号： A61K38/21 ,  A61K31/4035 ,  A61K31/416 ,  A61K31/437 ,  C07D209/44 ,  C07D471/04 ,  C07D231/54 ,  A61P31/12 ,  A61K31/505 ,  A61K31/52

    CPC分类号： C07D403/14 ,  C07D231/56 ,  C07D471/04

    摘要： The embodiments provide compounds of the general Formula I, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments provide compounds of the general Formula II, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments provide compounds of the general Formula III, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.

    摘要翻译： 实施方案提供了通式I的化合物，以及包含主题化合物的组合物，包括药物组合物。 实施方案提供了通式II的化合物，以及包含主题化合物的组合物，包括药物组合物。 实施方案提供了通式III的化合物，以及包含主题化合物的组合物，包括药物组合物。 实施方案还提供治疗方法，包括治疗丙型肝炎病毒感染的方法和治疗肝纤维化的方法，所述方法通常涉及向有需要的个体施用有效量的主题化合物或组合物。

    Synthetic hyperglycosylated, and hyperglycosylated protease-resistant polypeptide variants, oral formulations and methods of using the same
    8.
    发明申请
    Synthetic hyperglycosylated, and hyperglycosylated protease-resistant polypeptide variants, oral formulations and methods of using the same 有权

    公开(公告)号：US20060204473A1

    公开(公告)日：2006-09-14

    申请号：US11351163

    申请日：2006-02-08

    申请人： Lawrence Blatt ,  Scott Seiwert ,  Jin Hong

    发明人： Lawrence Blatt ,  Scott Seiwert ,  Jin Hong

    IPC分类号： A61K38/21 ,  C07K14/56 ,  C07K14/565 ,  C07K14/57

    CPC分类号： C07K14/555 ,  A61K38/00 ,  C07K14/56 ,  C07K14/565 ,  C07K14/57 ,  Y02A50/385 ,  Y02A50/387 ,  Y02A50/393

    摘要： The present invention provides synthetic Type I interferon receptor polypeptide agonists comprising consensus or hybrid Type I interferon receptor polypeptide agonists, containing one or more native or non-native glycosylation sites. The present invention provides synthetic Type I interferon receptor polypeptide agonists comprising consensus or hybrid Type I interferon receptor polypeptide agonists, containing one or more native or non-native glycosylation sites, as well as erythropoietin and darbepoetin alfa, each of which are linked to a penetrating peptide that facilitates translocation of a substance across a biological barrier as well as pharmaceutical compositions, including oral formulations, of the same. The present invention further provides oral formulations of hyperglycosylated or protease-resistant, hyperglycosylated polypeptide variants, which polypeptide variants lack at least one protease cleavage site found in a parent polypeptide, and thus exhibit increased protease resistance compared to the parent polypeptide, which polypeptide variants further include (1) a carbohydrate moiety covalently linked to at least one non-native glycosylation site not found in the parent protein therapeutic or (2) a carbohydrate moiety covalently linked to at least one native glycosylation site found but not glycosylated in the parent protein therapeutic. The present invention further provides compositions, including oral pharmaceutical compositions, comprising the synthetic Type I interferon receptor polypeptide agonist, the hyperglycosylated polypeptide variant, or the hyperglycosylated, protease-resistant polypeptide variant. The present invention further provides containers, devices, and kits comprising the synthetic Type I interferon receptor polypeptide agonist, the hyperglycosylated polypeptide variant, or the hyperglycosylated, protease-resistant polypeptide variant. The present invention further provides therapeutic methods involving administering an effective amount of an oral pharmaceutical composition comprising a synthetic Type I interferon receptor polypeptide agonist, a hyperglycosylated polypeptide variant, or a hyperglycosylated, protease-resistant polypeptide variant to an individual in need thereof.

    Use of pirfenidone in therapeutic regimens
    10.
    发明申请
    Use of pirfenidone in therapeutic regimens 失效
    吡非尼酮在治疗方案中的应用

    公开(公告)号：US20070117841A1

    公开(公告)日：2007-05-24

    申请号：US10574631

    申请日：2004-10-21

    申请人： Osman Ozes ,  Lawrence Blatt ,  Scott Seiwert

    发明人： Osman Ozes ,  Lawrence Blatt ,  Scott Seiwert

    IPC分类号： A61K31/47

    CPC分类号： A61K31/47 ,  A61K31/4412 ,  A61K38/212 ,  A61K38/217 ,  A61K45/06 ,  G01N33/5091 ,  Y02A50/411 ,  A61K2300/00

    摘要： The present invention provides methods for treating a disorder, and methods for inhibiting a stress-activated protein kinase (SAPK) in a cell in an individual, the methods generally involving administering to an individual in need thereof an effective amount of pirfenidone or a pirfenidone analog; comparing a post-treatment SAPK activity level in a biological sample from the individual with a pre-treatment SAPK activity level; and adjusting the dose of the pirfenidone or pirfenidone analog based on the results of the comparison step. The present invention provides methods for treating a disorder, and methods for inhibiting a SAPK in a cell in an individual, the methods generally involving administering to an individual in need thereof an effective amount of pirfenidone or a pirfenidone analog; comparing a second post-treatment SAPK activity level in a biological sample from the individual with a first post-treatment SAPK activity level; and adjusting the dose of the pirfenidone or pirfenidone analog based on the results of the comparison step.

    摘要翻译： 本发明提供了治疗病症的方法以及在个体细胞中抑制应激活化蛋白激酶（SAPK）的方法，所述方法通常涉及向有需要的个体施用有效量的吡非尼酮或吡非尼酮类似物 ; 将来自个体的生物样品中的后处理SAPK活性水平与预处理SAPK活性水平进行比较; 并根据比较步骤的结果调整吡非尼酮或吡非尼酮类似物的剂量。 本发明提供了治疗病症的方法以及在个体细胞中抑制SAPK的方法，所述方法通常涉及向有需要的个体施用有效量的吡非尼酮或吡非尼酮类似物; 将来自个体的生物样品中的第二后处理SAPK活性水平与第一后处理SAPK活性水平进行比较; 并根据比较步骤的结果调整吡非尼酮或吡非尼酮类似物的剂量。